CLCS Stock Chart & Stats
$0.82
$0.03(3.24%)
At close: 4:00 PM EDT
$0.82
$0.03(3.24%)
Day’s Range― - ―
52-Week Range$0.25 - $2.25
Previous CloseN/A
Volume1.20K
Average Volume (3M)4.44K
Market Cap
$44.61M
Enterprise Value$45.08M
Total Cash (Recent Filing)$74.63K
Total Debt (Recent Filing)$10.07M
Price to Earnings (P/E)―
Beta-0.71
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding68,857,376
10 Day Avg. Volume11,735
30 Day Avg. Volume4,444
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-1.21
Price to Sales (P/S)0.00
P/FCF Ratio-9.95
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cell Source News
CLCS FAQ
What was Cell Source Inc’s price range in the past 12 months?
Cell Source Inc lowest stock price was $0.25 and its highest was $2.25 in the past 12 months.
What is Cell Source Inc’s market cap?
Cell Source Inc’s market cap is $44.61M.
When is Cell Source Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cell Source Inc’s earnings last quarter?
Currently, no data Available
Is Cell Source Inc overvalued?
According to Wall Street analysts Cell Source Inc’s price is currently Overvalued.
Does Cell Source Inc pay dividends?
Cell Source Inc does not currently pay dividends.
What is Cell Source Inc’s EPS estimate?
Cell Source Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cell Source Inc have?
Cell Source Inc has 68,857,376 shares outstanding.
What happened to Cell Source Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cell Source Inc?
Currently, no hedge funds are holding shares in CLCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cell Source Inc
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.